A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.

"Conflict-of-interest disclosure: M.Y.L. has received an honorarium for participation in advisory boards from Takeda, Dova Pharmaceuticals, and Forma Therapeutics. M.Y.A-I. has participated on advisory boards with Sanofi. X.L.Z. services as a member of the advisory boards for Takeda, Sanofi, and Alexion. X.L.Z. is a cofounder of Clotsolution and is supported in part from 10.13039/100000050National Heart, Lung, and Blood Institute (R01 HL126724 and HL144552). G.d.R. serves the speaker bureaus for Sanofi and advisory boards for Mallinckrodt. R.G. has received research funding from the 10.13039/100000050National Heart, Lung, and Blood Institute (K08 HL159290). R.G. served as a consultant and participated on the advisory boards for Sanofi, Takeda, and Alexion. The remaining authors declare no competing financial interests."

"This investigation was supported in part by the 10.13039/100006108National Center for Advancing Translational Sciences of the 10.13039/100000002National Institutes of Health under award number UL1TR002538."